RMA Delays
Our Admin Portal website is currently experiencing technical difficulties, and it could result in delays with RMAs being processed. We are currently working to resolve these issues. We apologize for the inconvenience.Join us on August 11th for an ActiGraph webinar hosted by Xtalks:
Oncology Research and Care: Reimagining Digital Innovation
Register Now
Traversing the Regulatory Road to Qualifying a Digital Endpoint; Twists and Turns
Mobile in Clinical Trials virtual panel discussion, “Traversing the Regulatory Road to Qualifying a Digital Endpoint; Twists and Turns.” ActiGraph CEO, Jeremy Wyatt, joined a panel of thought leaders from Pfizer, Boehringer Ingelheim, Biogen, and ICON to discuss a framework for the qualification of novel digital endpoints and the regulatory feedback on these approaches. Topics covered include:
- Regulatory engagements that included discussions of NDE(s)
- Case studies that organizations have put forward, the types of information collected, questions asked to health authorities, their context and objectives, as well as responses from health authorities
- Insights we can leverage as we go forward
- Jeremy Wyatt, CEO, ActiGraph
- Robert Joe Mather, Executive Director, Digital Medicine & Translational Imaging, Early Clinical Development, Pfizer
- Mohammed Ali, Global Head, Digital Trials & Clinical Operations, Boehringer Ingelheim
- Kelley Erb, Director, Digital and Quantitative Medicine, Biogen
- Carrie Northcott, PhD, Director, Early Clinical Development, Digital Medicine and Translational Imaging, Pfizer
- Marie McCarthy, MBA, Senior Director, Product Innovation, ICON